Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | CBFB | Q13951 | 1/20 | 0.33 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16132453 | 0.81 | MAPT (0.47) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL16132303 | 0.78 | MAPT (0.44) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL29933557 | 0.78 | NSD2 (0.54) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL4071537 | 0.78 | NSD2 (0.54) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL28036407 | 0.78 | KDM4E (0.47) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL16110778 | 0.75 | MAPT (0.52) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL29862875 | 0.74 | KMT2A (0.50) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL19836985 | 0.74 | KMT2A (0.50) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL27032808 | 0.73 | MAPT (0.46) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL30878064 | 0.72 | KMO (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105102453-B | benzimidazolone derivatives as bromodomain inhibitors | 吉利德科学公司 | 2018-04-06 | — | — | CN | disclosed |
| EP-2978759-B1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2978759-B1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9255089-B2 | Benzimidazolone derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255089-B2 | Benzimidazolone derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| EP-2978759-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | Gilead Sciences, Inc. (US) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014160873-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160873-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MAPT 1994/4885KDM4E 209/4885CYP3A4 3554/4885 |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MAPT 1994/4885KDM4E 209/4885CYP3A4 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.